Anionic Polymer Conjugates for Hydrophobic Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems, particularly those using PEG-based block copolymers, face challenges with non-biodegradability and limited release profiles for hydrophobic drugs like paclitaxel, which affects therapeutic efficacy and tumor targeting.
Innovation Solution
Development of anionic polymer conjugates with covalently attached hydrophobic moieties, such as diethylnicotinamide and dimethylbenzamide, forming biodegradable polymer micelles that encapsulate hydrophobic drugs, enhancing solubility and release profiles, and improving tumor accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If PEG-based block copolymers are used to form polymer micelles for hydrophobic drug delivery, then drug solubility is improved, but the system becomes non-biodegradable and release profile is limited
Solution Approach 1:
The patent uses composite polymer structures combining hydrophilic blocks (for solubility and micelle formation) with hydrophobic blocks (for drug encapsulation). The specific composite design incorporates biodegradable linkages that allow controlled degradation and drug release, resolving the contradiction between maintaining drug solubility through micelle formation and enabling biodegradability for improved release profiles.
Solution Approach 2:
The patent modifies the chemical parameters of the polymer system by incorporating specific biodegradable linkages (such as ester bonds) into the polymer backbone. This parameter change enables the polymer to degrade under physiological conditions, transforming the system from non-biodegradable to biodegradable while maintaining its micelle-forming and drug-solubilizing capabilities.
2Quantity of substance
If conventional polymer micelles are used for drug delivery, then drug encapsulation is achieved, but tumor accumulation and therapeutic efficacy are limited
Solution Approach 1:
The patent applies local quality modifications by incorporating specific functional groups and hydrophobic-hydrophilic block arrangements that enhance the micelle's interaction with tumor tissues. The localized structural features (such as specific hydrophobic block compositions) improve tumor accumulation through enhanced permeability and retention effects, thereby increasing therapeutic efficacy while maintaining drug encapsulation capabilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer conjugate system demonstrates enhanced therapeutic efficacy by improving drug solubility, prolonging plasma circulation, and achieving higher tumor accumulation and release of paclitaxel, outperforming conventional Abraxane® in cancer treatment models.
Implementation Method 1
The poorly soluble drugs are encapsulated in the latter via hydrophobic interaction with the hydrophobic portion of the copolymer
Implementation Method 2
providing a hydrophilic outer shell and a hydrophobic inner core. The poorly soluble drugs are encapsulated in the latter
Implementation Method 3
achieving higher tumor accumulation and release of paclitaxel, outperforming conventional Abraxane® in cancer treatment models
Data Source
AI summary
Polymer conjugates characterized in that the backbone of the polymer is an anionic polymer and hydrophobic moieties are covalently attached to the polymer backbone are useful for preparing drug encapsulated polymer hydrotropes and compositions. Such materials are useful in methods for delivering the drug into cells, and for the treatment and alleviation of diseases and disorders such as cancer.